{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Bone&page=33",
    "query": {
      "condition": "Cancer Bone",
      "page": 33
    },
    "page_size": 10
  },
  "pagination": {
    "page": 33,
    "page_size": 10,
    "total_count": 3411,
    "total_pages": 342,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Bone&page=34&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Bone&page=32&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-16T19:07:21.522Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04994808",
      "title": "Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Clofarabine",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Hematopoietic Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Treosulfan",
          "type": "DRUG"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Lumbar Puncture",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 23,
      "start_date": "2023-08-11",
      "completion_date": "2026-07-16",
      "has_results": false,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-11-16T19:07:21.522Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04994808"
    },
    {
      "nct_id": "NCT00720174",
      "title": "Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Angiosarcoma",
        "Adult Desmoplastic Small Round Cell Tumor",
        "Adult Epithelioid Sarcoma",
        "Adult Extraskeletal Myxoid Chondrosarcoma",
        "Adult Extraskeletal Osteosarcoma",
        "Adult Fibrosarcoma",
        "Adult Leiomyosarcoma",
        "Adult Liposarcoma",
        "Adult Malignant Mesenchymoma",
        "Adult Malignant Peripheral Nerve Sheath Tumor",
        "Adult Rhabdomyosarcoma",
        "Adult Synovial Sarcoma",
        "Adult Undifferentiated High Grade Pleomorphic Sarcoma of Bone",
        "Childhood Angiosarcoma",
        "Childhood Desmoplastic Small Round Cell Tumor",
        "Childhood Epithelioid Sarcoma",
        "Childhood Fibrosarcoma",
        "Childhood Leiomyosarcoma",
        "Childhood Liposarcoma",
        "Childhood Malignant Mesenchymoma",
        "Childhood Malignant Peripheral Nerve Sheath Tumor",
        "Childhood Pleomorphic Rhabdomyosarcoma",
        "Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features",
        "Childhood Synovial Sarcoma",
        "Dermatofibrosarcoma Protuberans",
        "Malignant Adult Hemangiopericytoma",
        "Malignant Childhood Hemangiopericytoma",
        "Metastatic Childhood Soft Tissue Sarcoma",
        "Previously Treated Childhood Rhabdomyosarcoma",
        "Recurrent Adult Soft Tissue Sarcoma",
        "Recurrent Childhood Rhabdomyosarcoma",
        "Recurrent Childhood Soft Tissue Sarcoma",
        "Stage III Adult Soft Tissue Sarcoma",
        "Stage IV Adult Soft Tissue Sarcoma",
        "Untreated Childhood Rhabdomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Cixutumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2008-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-05-17",
      "last_synced_at": "2026-11-16T19:07:21.522Z",
      "location_count": 13,
      "location_summary": "Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 10 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Decatur",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Harvey",
          "state": "Illinois"
        },
        {
          "city": "Joliet",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00720174"
    },
    {
      "nct_id": "NCT00569660",
      "title": "Ph II Study of Azacitidine in Myelofibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2005-06",
      "completion_date": "2008-04",
      "has_results": true,
      "last_update_posted_date": "2012-08-07",
      "last_synced_at": "2026-11-16T19:07:21.522Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00569660"
    },
    {
      "nct_id": "NCT00506948",
      "title": "Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematological Malignancies",
        "Myelodysplastic Syndrome",
        "Leukemia",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Mycophenolate Mofetil (MMF)",
          "type": "DRUG"
        },
        {
          "name": "Thymoglobulin",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Stem Cell Transplant",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 13,
      "start_date": "2006-09",
      "completion_date": "2010-10",
      "has_results": true,
      "last_update_posted_date": "2020-09-24",
      "last_synced_at": "2026-11-16T19:07:21.522Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00506948"
    },
    {
      "nct_id": "NCT02506933",
      "title": "Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Acute Lymphoblastic Leukemia in Remission",
        "Acute Myeloid Leukemia in Remission",
        "Chronic Lymphocytic Leukemia",
        "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Cytomegaloviral Infection",
        "Hodgkin Lymphoma",
        "Lymphadenopathy",
        "Lymphoblastic Lymphoma",
        "Myelodysplastic Syndrome",
        "Myelofibrosis",
        "Myeloproliferative Neoplasm",
        "Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Multi-peptide CMV-Modified Vaccinia Ankara Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 102,
      "start_date": "2015-12-21",
      "completion_date": "2027-05-10",
      "has_results": true,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-11-16T19:07:21.522Z",
      "location_count": 3,
      "location_summary": "Duarte, California • Boston, Massachusetts • Houston, Texas",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02506933"
    },
    {
      "nct_id": "NCT07270978",
      "title": "Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasm"
      ],
      "interventions": [
        {
          "name": "CD33 FPBMC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2026-03-26",
      "completion_date": "2031-07",
      "has_results": false,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-11-16T19:07:21.522Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07270978"
    },
    {
      "nct_id": "NCT00463385",
      "title": "A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelofibrosis With Myeloid Metaplasia",
        "Myeloid Metaplasia",
        "Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Placebo to pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Placebo to prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 88,
      "start_date": "2007-04-01",
      "completion_date": "2013-12-31",
      "has_results": true,
      "last_update_posted_date": "2019-11-20",
      "last_synced_at": "2026-11-16T19:07:21.522Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Rochester, Minnesota • New York, New York + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00463385"
    },
    {
      "nct_id": "NCT00004215",
      "title": "Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anemia",
        "Leukemia",
        "Neutropenia",
        "Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "leridistim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "daunorubicin hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1999-08",
      "completion_date": "2000-08",
      "has_results": false,
      "last_update_posted_date": "2013-06-19",
      "last_synced_at": "2026-11-16T19:07:21.522Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004215"
    },
    {
      "nct_id": "NCT00012376",
      "title": "Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Accelerated Phase Chronic Myelogenous Leukemia",
        "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",
        "Adult Acute Myeloid Leukemia With Del(5q)",
        "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)",
        "Blastic Phase Chronic Myelogenous Leukemia",
        "Chronic Myelomonocytic Leukemia",
        "Chronic Phase Chronic Myelogenous Leukemia",
        "Paroxysmal Nocturnal Hemoglobinuria",
        "Previously Treated Myelodysplastic Syndromes",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Refractory Anemia",
        "Refractory Anemia With Ringed Sideroblasts",
        "Relapsing Chronic Myelogenous Leukemia",
        "Thrombocytopenia",
        "Untreated Adult Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "bryostatin 1",
          "type": "DRUG"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2001-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-09",
      "last_synced_at": "2026-11-16T19:07:21.522Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00012376"
    },
    {
      "nct_id": "NCT03418038",
      "title": "Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clonal Cytopenia of Undetermined Significance",
        "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Recurrent Hodgkin Lymphoma",
        "Recurrent Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Refractory Lymphoma",
        "Chronic Myelomonocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Ascorbic Acid",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Placebo Administration",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Core Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Central Venous Cannula Insertion",
          "type": "PROCEDURE"
        },
        {
          "name": "Portacath Placement",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Decitabine and Cedazuridine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG",
        "OTHER",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2018-03-23",
      "completion_date": "2033-11-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-11-16T19:07:21.522Z",
      "location_count": 4,
      "location_summary": "Mankato, Minnesota • Rochester, Minnesota • Eau Claire, Wisconsin + 1 more",
      "locations": [
        {
          "city": "Mankato",
          "state": "Minnesota"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Eau Claire",
          "state": "Wisconsin"
        },
        {
          "city": "La Crosse",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03418038"
    }
  ]
}